GlassScriptPhysician profile
Dominique N Moore
NPI 1063294205
$1,480.48
in general payments reported to CMS, 2019-2025
19 companies · $83.60 in 2025
The $83.60 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $129 · 2024: $1,268 · 2025: $83.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.33 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $297.62 | 2023-2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $220.65 | 2024-2025 | Cobenfy |
| Abbvie INC. | $219.59 | 2023-2024 | |
| Axsome Therapeutics, INC. | $90.81 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $90.68 | 2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $79.77 | 2024 | Spravato |
| Neurocrine Biosciences, INC. | $73.18 | 2024 | Ingrezza |
| Lundbeck LLC | $71.93 | 2023-2024 | Rexulti |
| Corium, LLC | $60.04 | 2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $59.25 | 2024 | Rexulti, Abilify Asimtufii, Nuedexta |
| Alkermes, INC. | $56.82 | 2023-2024 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $35.44 | 2023-2024 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $29.86 | 2024 | Qelbree |
| Tris Pharma INC | $18.49 | 2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $18.28 | 2024 | Secuado, Xelstrym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17.34 | 2024 | Austedo Xr |
| Almatica Pharma LLC | $13.81 | 2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $13.49 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $13.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dominique Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.